Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) have been assigned a consensus recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $54.14.
A number of research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $125.00 price target on shares of Vir Biotechnology in a report on Thursday, July 14th. Morgan Stanley initiated coverage on Vir Biotechnology in a report on Friday. They set an “underweight” rating and a $15.00 target price on the stock. Finally, Barclays reduced their target price on Vir Biotechnology to $67.00 in a report on Monday, August 15th.
Insider Transactions at Vir Biotechnology
In related news, insider Phillip Pang sold 4,991 shares of Vir Biotechnology stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $24.89, for a total transaction of $124,225.99. Following the completion of the sale, the insider now owns 144,000 shares of the company’s stock, valued at $3,584,160. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Vir Biotechnology news, Director Vicki L. Sato sold 17,915 shares of the firm’s stock in a transaction dated Friday, July 8th. The stock was sold at an average price of $29.06, for a total transaction of $520,609.90. Following the transaction, the director now directly owns 1,470,664 shares in the company, valued at $42,737,495.84. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Phillip Pang sold 4,991 shares of the firm’s stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $24.89, for a total value of $124,225.99. Following the transaction, the insider now owns 144,000 shares in the company, valued at $3,584,160. The disclosure for this sale can be found here. Insiders sold a total of 173,385 shares of company stock valued at $4,767,741 over the last quarter. Company insiders own 22.40% of the company’s stock.
Hedge Funds Weigh In On Vir Biotechnology
Vir Biotechnology Trading Up 0.5 %
Vir Biotechnology stock opened at $22.38 on Monday. The firm has a market capitalization of $2.97 billion, a P/E ratio of 2.79 and a beta of -0.29. The stock has a fifty day moving average price of $27.15 and a 200 day moving average price of $24.90. Vir Biotechnology has a 52 week low of $18.21 and a 52 week high of $58.00.
Vir Biotechnology (NASDAQ:VIR – Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.41). Vir Biotechnology had a return on equity of 68.86% and a net margin of 52.29%. The firm had revenue of $40.60 million for the quarter, compared to analyst estimates of $211.14 million. During the same quarter in the prior year, the company earned $0.46 earnings per share. The business’s revenue was down 77.1% compared to the same quarter last year. As a group, equities analysts predict that Vir Biotechnology will post 3.14 EPS for the current year.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here’s Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.